Display options
Cite
Keller KE, Kopczynski C. Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study. J Clin Med. 2020;9(11)doi: 10.3390/jcm9113524.
Keller, K. E., & Kopczynski, C. (2020). Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study. Journal of clinical medicine, 9(11), . https://doi.org/10.3390/jcm9113524
Keller, Kate E, and Kopczynski, Casey. "Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study." Journal of clinical medicine vol. 9,11 (2020). doi: https://doi.org/10.3390/jcm9113524
Keller KE, Kopczynski C. Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study. J Clin Med. 2020 Oct 31;9(11). doi: 10.3390/jcm9113524. PMID: 33142742; PMCID: PMC7693753.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2020 Oct 31;9(11). doi: 10.3390/jcm9113524.

Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging Study.

Journal of clinical medicine

Kate E Keller, Casey Kopczynski

Affiliations

  1. Casey Eye Institute, Oregon Health & Science University, Portland, OR 97239, USA.
  2. Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR 97239, USA.
  3. Aerie Pharmaceuticals, Durham, NC 27703, USA.

PMID: 33142742 PMCID: PMC7693753 DOI: 10.3390/jcm9113524

Abstract

The actin cytoskeleton of trabecular meshwork (TM) cells is a therapeutic target for lowering intraocular pressure (IOP) in glaucoma patients. Netarsudil (the active ingredient in Rhopressa

Keywords: actin cytoskeleton; extracellular vesicles; glaucoma; live cell imaging; trabecular meshwork; tunneling nanotubes

References

  1. Exp Eye Res. 2000 Mar;70(3):307-13 - PubMed
  2. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5769-77 - PubMed
  3. Exp Eye Res. 2015 Apr;133:112-25 - PubMed
  4. Expert Rev Ophthalmol. 2012 Apr;7(2):177-187 - PubMed
  5. J Cell Sci. 2018 Jul 19;131(14): - PubMed
  6. Invest Ophthalmol Vis Sci. 1998 Sep;39(10):1804-12 - PubMed
  7. Transl Vis Sci Technol. 2020 Sep 25;9(10):27 - PubMed
  8. Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12856-12867 - PubMed
  9. Exp Eye Res. 2018 Jun;171:164-173 - PubMed
  10. Nat Rev Mol Cell Biol. 2008 Jun;9(6):431-6 - PubMed
  11. Nat Methods. 2014 Jul;11(7):731-3 - PubMed
  12. Cells. 2018 Oct 13;7(10): - PubMed
  13. Exp Eye Res. 2015 Mar;132:73-7 - PubMed
  14. Curr Med Chem. 2009;16(11):1355-65 - PubMed
  15. Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3187-92 - PubMed
  16. Sci Rep. 2016 Feb 17;6:21315 - PubMed
  17. Science. 2004 Feb 13;303(5660):1007-10 - PubMed
  18. Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):101-109 - PubMed
  19. J Glaucoma. 2015 Jan;24(1):51-4 - PubMed
  20. Neural Regen Res. 2020 Nov;15(11):2031-2032 - PubMed
  21. Acta Biomater. 2018 Apr 15;71:444-459 - PubMed
  22. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6197-6209 - PubMed
  23. J Biol Chem. 2005 Aug 12;280(32):28917-26 - PubMed
  24. J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):40-51 - PubMed
  25. Proc Natl Acad Sci U S A. 2020 May 12;117(19):10339-10349 - PubMed
  26. Invest Ophthalmol Vis Sci. 1990 Oct;31(10):2156-63 - PubMed
  27. Prog Retin Eye Res. 2013 Nov;37:1-12 - PubMed
  28. Invest Ophthalmol Vis Sci. 2019 Feb 1;60(2):843-851 - PubMed
  29. Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1313-8 - PubMed
  30. Exp Eye Res. 2017 May;158:23-32 - PubMed
  31. Cell. 2004 Apr 30;117(3):361-72 - PubMed
  32. Prog Retin Eye Res. 2017 Jul;59:158-177 - PubMed
  33. Nat Methods. 2012 Jun 28;9(7):676-82 - PubMed
  34. Eur J Pharmacol. 2016 Sep 15;787:20-31 - PubMed
  35. Ophthalmologica. 1997;211(3):147-52 - PubMed
  36. Invest Ophthalmol Vis Sci. 2011 Apr 05;52(5):2147-52 - PubMed
  37. Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4583-4595 - PubMed
  38. Trends Cell Biol. 2009 Apr;19(4):174-9 - PubMed
  39. Exp Eye Res. 2017 May;158:112-123 - PubMed
  40. Exp Eye Res. 2017 May;158:124-136 - PubMed
  41. Sci Rep. 2019 Mar 1;9(1):3241 - PubMed
  42. Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228 - PubMed
  43. Proteomics. 2013 May;13(10-11):1624-36 - PubMed
  44. J Huazhong Univ Sci Technolog Med Sci. 2016 Feb;36(1):31-36 - PubMed
  45. Curr Opin Cell Biol. 2004 Aug;16(4):422-8 - PubMed
  46. Trends Cell Biol. 2018 Sep;28(9):685-697 - PubMed
  47. Biochem Soc Trans. 1995 Aug;23(3):456-9 - PubMed
  48. Science. 2009 Nov 27;326(5957):1208-12 - PubMed
  49. J Proteomics. 2011 May 16;74(6):796-804 - PubMed
  50. Biochem J. 2000 Oct 1;351(Pt 1):95-105 - PubMed
  51. Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5298-5307 - PubMed
  52. Mol Biol Cell. 2013 Apr;24(8):1095-8 - PubMed
  53. Stem Cell Reports. 2018 Mar 13;10(3):1075-1087 - PubMed
  54. Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2884-2890 - PubMed
  55. J Ocul Pharmacol Ther. 2018 Jun;34(5):380-386 - PubMed
  56. Exp Eye Res. 2016 Apr;145:393-400 - PubMed
  57. Biomed Res Int. 2020 Apr 8;2020:7246785 - PubMed
  58. J Cell Sci. 2017 Feb 1;130(3):525-530 - PubMed
  59. Curr Biol. 2014 Jul 21;24(14):1628-1635 - PubMed
  60. Nat Cell Biol. 2009 Jan;11(1):71-7 - PubMed
  61. J Glaucoma. 1995 Jun;4(3):183-8 - PubMed
  62. Curr Eye Res. 2020 Sep 3;:1-8 - PubMed
  63. Bioorg Med Chem Lett. 2016 May 15;26(10):2475-2480 - PubMed
  64. Nat Cell Biol. 2007 Oct;9(10):1110-21 - PubMed
  65. Annu Rev Cell Dev Biol. 2014;30:255-89 - PubMed
  66. Exp Eye Res. 2007 Feb;84(2):275-84 - PubMed
  67. Nat Rev Mol Cell Biol. 2008 Jun;9(6):446-54 - PubMed
  68. Br J Ophthalmol. 1979 Jan;63(1):3-8 - PubMed
  69. Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37 - PubMed
  70. J Cell Sci. 2012 Mar 1;125(Pt 5):1073-9 - PubMed

Publication Types

Grant support